Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

Blood

Volumn 116, Issue 24, 2010, Pages 5111-5118

  Wingard, John R ^a   Carter, Shelly L ^b   Walsh, Thomas J ^c   Kurtzberg, Joanne ^d   Small, Trudy N ^e   Baden, Lindsey R ^f   Gersten, Iris D ^b   Mendizabal, Adam M ^b   Leather, Helen L ^a   Confer, Dennis L ^g   Maziarz, Richard T ^h   Stadtmauer, Edward A ⁱ   Bolaños Meade, Javier ^j   Brown, Janice ^k   DiPersio, John F ^l   Boeckh, Michael ^m   Marr, Kieren A ^j,m  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g NATIONAL MARROW DONOR PROGRAM   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k STANFORD UNIVERSITY   (United States)

^l WASHINGTON UNIVERSITY   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GALACTOMANNAN; PLACEBO; PREDNISONE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VISUAL DISORDER;

EID: 78650058029     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-268151     Document Type: Article

References (32)

1. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845-851.
2. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545-1552.
3. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med. 2003;138(9):705-713.
4. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527-1533. (Pubitemid 38168674)
5. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557-1559.
6. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus host disease. N Engl J Med. 2007;356(4):335-347.
7. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360.
8. Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004; 39(8):1241-1244.
9. den Hollander JG, van Arkel C, Rijnders BJ, et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother. 2006;57(6): 1248-1250. (Pubitemid 44644436)
10. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47(1):e7-e10.
11. Groll AH, Kolve H, Ehlert K, et al. Pharmacokinetic interaction between voriconazole and cyclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother. 2004;53(1): 113-114. (Pubitemid 38072193)
12. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(5):552-559.
13. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10): 1417-1427.
14. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373-379.
15. Maertens JA, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97(6):1604-1610.
16. Wingard JR. Design issues in a prospective, randomized, double-blinded trial of prophylaxis of fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2004;39(4):S176-S180.
17. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
21. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the TRANSNET database. Clin Infect Dis. 2010;50(8):1091-1100.
22. Cornely OA, Maerten J, Winston D, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
23. Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis. 2008;46(10):1626-1627.
24. De Pauw B, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med. 2007;356(4):409-411.
25. Trifilio S, Pennick G, Pi J, Zook J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007; 109(8):1532-1535.
26. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(suppl 1):S49-S58.
27. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44(4):531-540.
28. Nivoix Y, Nelton M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008; 47(9):1176-1184.
29. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950-952. (Pubitemid 38252550)
30. iwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39(4):584-587.
31. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350-1360.
32. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762-1768.